Terlipressin for Hepatorenal Syndrome and Bleeding

Terlipressin is a synthetic drug used primarily to treat two dangerous complications of advanced liver disease: hepatorenal syndrome, a form of kidney failure triggered by cirrhosis, and acute bleeding from variceal veins in the esophagus. It works by constricting blood vessels in the gut, redirecting blood flow toward the kidneys and raising blood pressure enough to restore kidney function in some patients. Used in dozens of countries for decades, terlipressin arrived late in the United States, gaining FDA approval only in 2022, and its safety profile in severely ill liver patients has made prescribing it more nuanced than the approval headlines suggested.

How Terlipressin Works in the Body

Terlipressin is technically a prodrug. Once injected, enzymes in the blood gradually clip off part of its structure and convert it into lysine-vasopressin, the active molecule. That slow conversion gives it a longer duration of action than natural vasopressin, which the body clears within minutes. But terlipressin itself is not just an inert shell waiting to be activated. Research has shown that the intact terlipressin molecule also binds directly to vasopressin receptors, acting as a partial agonist at the V1 receptor responsible for blood vessel constriction and a full agonist at the V2 receptor involved in water retention by the kidneys.¹ This dual action, both from the parent drug and its metabolite, helps explain why terlipressin has a relatively prolonged effect but also why it can cause side effects beyond its intended target.

The drug has roughly six times more affinity for the V1 receptor than V2, which is clinically useful because V1 receptors sit on the smooth muscle of splanchnic blood vessels, the ones feeding the gut and spleen. In advanced cirrhosis, those vessels dilate dramatically, pooling blood in the abdomen and starving the kidneys of flow. Terlipressin squeezes those dilated vessels back toward a normal diameter. An MRI-based study mapping blood flow changes after a terlipressin dose found that blood flow in the main artery feeding the gut dropped by about 27%, while renal artery blood flow rose by roughly 23%, and the kidneys’ share of total cardiac output jumped by nearly half.² In other words, terlipressin takes blood that was being wasted in an overly relaxed gut circulation and reroutes it to the kidneys.

Hepatorenal Syndrome and Why Terlipressin Matters

Hepatorenal syndrome (HRS) is one of the most feared complications of end-stage liver disease. The kidneys themselves are structurally fine; the problem is that cirrhosis so severely disrupts the body’s circulatory balance that kidney perfusion collapses. Without treatment, the acute form (now called HRS-AKI) carries extremely high mortality, often within weeks. Liver transplant is the definitive fix, but most patients need a bridge to keep their kidneys working long enough to reach the operating room or recover from the precipitating crisis.

The best evidence for terlipressin in HRS comes from large placebo-controlled trials. The CONFIRM trial, published in the New England Journal of Medicine, randomized roughly 300 patients and found that about 32% of patients receiving terlipressin plus albumin achieved verified reversal of HRS, compared with 17% given placebo plus albumin.³ A pooled analysis of two earlier randomized trials showed similar numbers: 27% reversal with terlipressin versus 14% with placebo, along with significantly better kidney filtration rates.⁴ An older placebo-controlled trial pegged the reversal rate at 34% versus 13%.⁵

These numbers may sound modest, but in a condition where the alternative is progressive kidney failure and death, roughly doubling the chance of kidney recovery is clinically meaningful, especially because HRS reversal itself is associated with significantly better survival.

How Terlipressin Compares With Other Vasoconstrictors

Terlipressin is not the only drug used to treat HRS. In countries where it was not available (the U.S., for example, prior to 2022), clinicians used either norepinephrine (a catecholamine given by continuous drip in the ICU) or the combination of midodrine plus octreotide (two oral/injectable drugs used outside the ICU). The question of which is better has generated a surprisingly contentious literature.

Head-to-head comparisons of terlipressin and norepinephrine have generally shown similar HRS reversal rates. One randomized trial found reversal in about 39% with terlipressin and 43% with norepinephrine, with no significant difference in short-term survival.⁶ Two separate meta-analyses pooling the available trials reached the same conclusion: no statistically significant difference in reversal or mortality between the two drugs.⁷⁸ However, the side effect profiles differ. Terlipressin tends to cause abdominal pain and diarrhea, while norepinephrine is more commonly associated with cardiovascular problems like chest pain and ischemia. The key practical difference is that norepinephrine requires an ICU bed and an arterial line for safe delivery, whereas terlipressin can be given on a regular hospital ward.

Against midodrine plus octreotide, the comparison is more one-sided. A randomized trial found that about 70% of patients on terlipressin recovered kidney function versus roughly 29% on midodrine-octreotide.⁹ A larger propensity-matched study confirmed this gap, showing HRS reversal in about 52% of terlipressin-treated patients compared with 20% on midodrine-octreotide, along with improved overall survival.¹⁰ The midodrine-octreotide combination, once common in U.S. practice, is now widely regarded as substantially less effective.

Variceal Bleeding

The other major indication for terlipressin is acute bleeding from esophageal varices, the swollen veins that develop when liver scarring forces blood to find alternative routes. These bleeds are medical emergencies. Terlipressin constricts the splanchnic vessels upstream of the varices, reducing pressure in the portal venous system and slowing or stopping the hemorrhage long enough for endoscopic treatment.

Studies measuring the portal pressure gradient show that terlipressin drops it quickly and keeps it down. One hemodynamic study found that a single dose reduced the pressure gradient by about 16 to 21% within 30 minutes, depending on the dose.¹¹ Compared with high-dose octreotide, another commonly used agent for variceal bleeding, terlipressin produced a more sustained pressure drop: the effect of octreotide tended to rebound after 10 minutes, while terlipressin’s continued to deepen over the full 30-minute observation window.¹²

The mortality data are striking. A Cochrane systematic review of multiple placebo-controlled trials found that terlipressin reduced all-cause mortality by about 34% compared to placebo in patients with acute variceal hemorrhage.¹³ That makes terlipressin the only vasoactive drug for variceal bleeding with a demonstrated mortality benefit against placebo in meta-analysis. In practice, though, a large three-arm randomized trial comparing terlipressin, somatostatin, and octreotide as add-ons to endoscopic therapy found no significant differences in bleeding control, rebleeding, or death among the three drugs.¹⁴ The implication is that when endoscopy is available promptly, the choice of vasoactive drug probably matters less than having any vasoactive drug running.

Safety Concerns and Who Should Not Get Terlipressin

Terlipressin’s vasoconstrictive power is a double-edged sword. Mild side effects like headache, abdominal cramps, and transient skin pallor are common and generally tolerable. More serious ischemic events, including heart attacks, gut ischemia, and skin necrosis, occur in fewer than 5% of cases.¹⁵ When skin necrosis does happen, it typically involves the extremities, though cases affecting the trunk and other areas have been reported.¹⁶

The safety concern that drew the most attention during the U.S. approval process was respiratory failure. In the CONFIRM trial, a meaningful subset of patients developed serious breathing problems. A review of the respiratory events from that trial and related data found that patients with fluid overload or very advanced liver failure (grade 3 acute-on-chronic liver failure) are at the highest risk.¹⁷ The mechanism likely involves terlipressin’s V2-receptor activity, which promotes water retention and can worsen fluid overload, pushing already-congested lungs past a tipping point. One study identified low baseline oxygen saturation as an independent predictor of respiratory failure with terlipressin.¹⁸

These findings have shaped prescribing in important ways. The FDA label carries warnings about respiratory failure in patients with volume overload or advanced acute-on-chronic liver failure, and it notes limited benefit when kidney function is severely impaired (serum creatinine above 5 mg/dL).¹⁹ Predictors of adverse events also include sepsis at baseline and higher bilirubin levels, suggesting that the sickest patients are at the greatest risk of both non-response and harm.²⁰ The practical upshot is that terlipressin works best and is safest when started earlier in the course of HRS, before patients spiral into multi-organ failure.

Bolus Versus Continuous Infusion

Terlipressin was traditionally given as intermittent intravenous boluses every four to six hours. More recently, continuous infusion has emerged as a preferred approach in many centers. The rationale is straightforward: a slow drip avoids the peaks and troughs in blood levels that come with boluses, potentially reducing side effects while maintaining the drug’s hemodynamic benefit.

A randomized trial comparing the two approaches in HRS patients found similar response rates (about 76% with continuous infusion versus 65% with bolus, a difference that was not statistically significant), but the continuous infusion group required a significantly lower daily dose, averaging roughly 2.2 mg per day compared to 3.5 mg per day with boluses.²¹ A more recent trial in patients with acute-on-chronic liver failure found that continuous infusion used about half the total terlipressin dose and produced zero serious side effects compared to 15 adverse events in the bolus group.²²

Portal pressure studies echo this story. When given by continuous infusion, portal venous pressure dropped and stayed down, whereas bolus dosing produced a sharp initial drop followed by a rebound back toward baseline.²³ The evolving consensus among hepatologists is that continuous infusion should be the default mode of delivery when feasible, particularly to reduce the risk of ischemic complications.

Cost and Access

Terlipressin’s cost is a significant factor in where and how it gets used. In the United States, where it carries a branded price, pharmacy costs are high. A cost-effectiveness analysis from the U.S. hospital perspective found that the total cost per complete HRS response was around $452,000 for terlipressin plus albumin. That sounds enormous, but it was roughly half the per-response cost of norepinephrine plus albumin (about $931,000), primarily because norepinephrine requires expensive ICU stays, whereas terlipressin can be administered on a general ward.²⁴ Midodrine-octreotide looked even worse, with a per-response cost exceeding $4.9 million, largely because it is so much less effective.

Outside the U.S., the economics look very different. A Brazilian analysis in a public healthcare system found that terlipressin plus albumin cost only about $1,644 per treatment course and was cost-effective against both albumin alone and norepinephrine-based regimens.²⁵ A Thai analysis similarly found terlipressin cost-effective when measured against quality-adjusted life years gained.²⁶ The gap reflects the much lower generic terlipressin prices available outside the U.S. In practical terms, this means that for many hospitals worldwide, the main barrier is not cost but drug availability and physician familiarity, while in American hospitals the conversation about terlipressin often starts and ends with budget committees.

Use in Septic Shock

Beyond liver disease, terlipressin has attracted interest as a rescue vasopressor in septic shock, the severe drop in blood pressure caused by overwhelming infection. When standard drugs like norepinephrine and epinephrine fail to maintain adequate blood pressure at high doses, clinicians are left with few options. Terlipressin, with its sustained vasoconstrictive effect, has been considered a potential add-on in these refractory cases.²⁷

A recent randomized, placebo-controlled trial tested this directly. Patients in refractory septic shock who were randomized to receive terlipressin on top of their standard vasopressors were more likely to have their catecholamine requirements reduced at 6 hours: roughly 23% met the primary outcome with terlipressin versus 9% with placebo. However, there was no significant difference in mortality or in the rate of digital ischemia, a concern given the drug’s vasoconstrictive nature.²⁸ Small studies in children with catecholamine-resistant septic shock have similarly found that terlipressin raised blood pressure and improved oxygenation, though again without a clear mortality benefit.²⁹ The bottom line for septic shock is that terlipressin can help stabilize hemodynamics in desperate situations, but its role remains that of a rescue option rather than a first-line agent.

Pediatric Considerations

Children with advanced liver disease can develop HRS and variceal bleeding just as adults do, but pediatric data on terlipressin remain sparse. A prospective study in critically ill children with liver disease found that terlipressin raised blood pressure in a sustained manner and showed trends toward improved kidney function, particularly in the subset with HRS, with minimal side effects such as mild gastrointestinal intolerance and rare peripheral cyanosis.³⁰ A small case series of four pediatric HRS patients also suggested safety and efficacy but emphasized how much the field still lacks standardized dosing and diagnostic criteria adapted for children.³¹ At this point, pediatric use of terlipressin is essentially off-label, guided by adult data and institutional experience rather than robust randomized evidence.

Predicting Who Will Respond

One of the frustrations with terlipressin is that even in the best trials, a majority of patients with HRS do not achieve full reversal. Identifying who is likely to benefit, and who faces risk without realistic reward, has become an active area of research. In a prospective study of patients with acute-on-chronic liver failure and HRS, baseline serum creatinine above roughly 3 mg/dL predicted non-response with good accuracy. Early changes in blood pressure also helped: patients whose mean arterial pressure rose by at least 4.5 mmHg within the first three days were more likely to respond.³² Higher grades of acute-on-chronic liver failure also strongly predicted non-response, consistent with the idea that once organ failure cascades past a certain point, a drug targeting one piece of the circulatory puzzle cannot rescue the whole system.

For clinicians, these findings translate into a practical approach: start terlipressin early, watch the creatinine and blood pressure closely over the first few days, and be ready to reassess quickly if there is no signal of improvement. There is little evidence supporting prolonged courses in patients who show no response by about day three to five, and continuing the drug in that setting adds risk without clear benefit.